| 5.38 -0.03 (-0.55%) | 10-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.3 |
1-year : | 6.36 |
| Resists | First : | 5.4 |
Second : | 5.44 |
| Pivot price | 5.38  |
|||
| Supports | First : | 5.32 |
Second : | 4.42 |
| MAs | MA(5) : | 5.4 |
MA(20) : | 5.37 |
| MA(100) : | 5.24 |
MA(250) : | 4.02 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 58.3 |
D(3) : | 69.4 |
| RSI | RSI(14): 46.6 |
|||
| 52-week | High : | 5.71 | Low : | 2.36 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CVAC ] has closed above bottom band by 35.1%. Bollinger Bands are 78.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 69 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.45 - 5.48 | 5.48 - 5.5 |
| Low: | 5.32 - 5.37 | 5.37 - 5.4 |
| Close: | 5.35 - 5.42 | 5.42 - 5.46 |
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Thu, 09 Oct 2025
CureVac (NASDAQ:CVAC) Earns "Hold (C-)" Rating from Weiss Ratings - MarketBeat
Fri, 03 Oct 2025
CureVac N.V. (NASDAQ:CVAC) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Wed, 01 Oct 2025
CureVac: The Hidden Value Of The mRNA Wallet - Seeking Alpha
Fri, 01 Aug 2025
CureVac N.V. (CVAC) Stock Analysis: Navigating the Volatile Biotech Sector with mRNA Innovation - DirectorsTalk Interviews
Sun, 15 Jun 2025
There's No Escaping CureVac N.V.'s (NASDAQ:CVAC) Muted Revenues Despite A 50% Share Price Rise - simplywall.st
Thu, 12 Jun 2025
CureVac stock soars about 30% after BioNTech agrees to acquire co - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 225 (M) |
| Held by Insiders | 1.2587e+008 (%) |
| Held by Institutions | 57.3 (%) |
| Shares Short | 670 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 2.4867e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 37.9 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 959.4 % |
| Return on Equity (ttm) | 23.7 % |
| Qtrly Rev. Growth | 5.1051e+008 % |
| Gross Profit (p.s.) | -36.42 |
| Sales Per Share | 16.02 |
| EBITDA (p.s.) | 1.92908e+008 |
| Qtrly Earnings Growth | 1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 204 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.33 |
| Price to Cash Flow | 5.18 |
| Dividend | 0 |
| Forward Dividend | 1.18e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|